ArticlePloS one2010
Delineation of the innate and adaptive T-cell immune outcome in the human host in response to Campylobacter jejuni infection.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 64 citations in OpenAlex.
- The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial.Nature communications · 2025Trial
- Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge model.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Trial
- ComparingGut microbes · 2025Article
- Tofacitinib ameliorates Campylobacter-induced intestinal pathology by suppressing IFNγ producing ILCs and T cells.Mucosal immunology · 2025Article
- Intestinal Barrier in Post-Biomolecules · 2023Article
- Modulation of innate lymphoid cells by enteric bacterial pathogens.Frontiers in immunology · 2023Review
- Th1/Th17-mediated Immunity and Protection from Peripheral Neuropathy in Wildtype and IL10Comparative medicine · 2022Article
- (Not) Home alone: Antigen presenting cell - T Cell communication in barrier tissues.Frontiers in immunology · 2022Review
- Innate Lymphoid Cells in Response to Intracellular Pathogens: ProtectionFrontiers in cellular and infection microbiology · 2021Review
- Human Campylobacteriosis-A Serious Infectious Threat in a One Health Perspective.Current topics in microbiology and immunology · 2021Review
- Resveratrol PreventsFrontiers in pharmacology · 2021Article
- Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis.JHEP reports : innovation in hepatology · 2020Article
- IL-23 Contributes toFrontiers in immunology · 2020Article
- Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL).Frontiers in immunology · 2020Review
- "High Treg" Inflammations Promote (Most) Non-Hematologic Cancers While "Low Treg" Inflammations Promote Lymphoid Cancers.Journal of inflammation research · 2020Article
- Human Immunity AgainstImmune network · 2019Review
- In vitro spleen cell cytokine responses of adult mice immunized with a recombinant PorA (major outer membrane protein [MOMP]) from Campylobacter jejuni.Scientific reports · 2019Article
- Role of putative virulence traits of Campylobacter jejuni in regulating differential host immune responses.Journal of microbiology (Seoul, Korea) · 2019Article
- Infectious bursal disease virus inoculation infection modifiesGut pathogens · 2018Article
- The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCampylobacter jejuni is the most prevalent cause of bacterial gastroenteritis worldwide. Despite the significant health burden this infection presents, molecular understanding of C. jejuni-mediated disease pathogenesis remains poorly defined. Here, we report the characterisation of the early, innate immune response to C. jejuni using an ex-vivo human gut model of infection. Secondly, impact of bacterial-driven dendritic cell activation on T-cell mediated immunity was also sought. METHODOLOGY: Healthy, control paediatric terminal ileum or colonic biopsy tissue was infected with C. jejuni for 8-12 hours. Bacterial colonisation was followed by confocal microscopy and mucosal innate immune responses measured by ELISA. Marked induction of IFNγ with modest increase in IL-22 and IL-17A was noted. Increased mucosal IL-12, IL-23, IL-1β and IL-6 were indicative of a cytokine milieu that may modulate subsequent T-cell mediated immunity. C. jejuni-driven human monocyte-derived dendritic cell activation was followed by analyses of T cell immune responses utilising flow cytometry and ELISA. Significant increase in Th-17, Th-1 and Th-17/Th-1 double-positive cells and corresponding cytokines was observed. The ability of IFNγ, IL-22 and IL-17 cytokines to exert host defence via modulation of C. jejuni adhesion and invasion to intestinal epithelia was measured by standard gentamicin protection assay.
conclusionsBoth innate and adaptive T cell-immunity to C. jejuni infection led to the release of IFNγ, IL-22 and IL-17A; suggesting a critical role for this cytokine triad in establishing host anti-microbial immunity during the acute and effectors phase of infection. In addition, to their known anti-microbial functions; IL-17A and IL-17F reduced the number of intracellular C. jejuni in intestinal epithelia, highlighting a novel aspect of how IL-17 family members may contribute to protective immunity against C. jejuni.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.